UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version)

Kanzo, 2021/12/01, Vol.62(12), pp.823-829

2021

Volltextzugriff (PDF)

P32 - AUTORECIST : utilisation de l'intelligence artificielle pour prédire la réponse RECIST

Journal of Epidemiology and Population Health, 2024-05, Vol.72

2024

Volltextzugriff (PDF)

肝癌治療効果判定基準（第6版）（2021年改訂版）

肝臓, 2021/12/01, Vol.62(12), pp.823-829

2021

Volltextzugriff (PDF)

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know

American journal of roentgenology (1976), 2010-08, Vol.195 (2), p.281-289

2010

Volltextzugriff (PDF)

mRECIST for HCC: Performance and novel refinements

Journal of hepatology, 2020-02, Vol.72 (2), p.288-306

2020

Volltextzugriff (PDF)

RECIST 1.1—Update and clarification: From the RECIST committee

European journal of cancer (1990), 2016-07, Vol.62, p.132-137

2016

Volltextzugriff (PDF)

Dedicated software to harmonize the follow-up of oncological patients

Research in Diagnostic and Interventional Imaging (Online), 2024-12, Vol.12, p.100051, Article 100051

2024

Volltextzugriff (PDF)

Création d’un outil électronique d’évaluation de la réponse thérapeutique par l’imagerie en oncologie : le projet EVA

Revue d'épidémiologie et de santé publique, 2020-09, Vol.68, p.S121-S122

2020

Volltextzugriff (PDF)

Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST

Seminars in liver disease, 2014-11, Vol.34 (4), p.444-455

2014

Volltextzugriff (PDF)

CO2.4 - Modèle multi-états pour l'estimation du meilleur timing de contrôle scannographique de progression du cancer du sein métastatique

Journal of Epidemiology and Population Health, 2024-05, Vol.72, p.202405, Article 202405

2024

Volltextzugriff (PDF)

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

European journal of nuclear medicine and molecular imaging, 2021-02, Vol.48 (2), p.469-476

2021

Volltextzugriff (PDF)

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

European journal of cancer (1990), 2016-07, Vol.62, p.138-145

2016

Volltextzugriff (PDF)

Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)

Hepatology research, 2022-04, Vol.52 (4), p.329-336

2022

Volltextzugriff (PDF)

Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations

Neoplasia (New York, N.Y.), 2024-07, Vol.53, p.101006-101006, Article 101006

2024

Volltextzugriff (PDF)

Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer

Annals of surgery, 2021-04, Vol.273 (4), p.806-813

2021

Volltextzugriff (PDF)

Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study

Lung cancer (Amsterdam, Netherlands), 2019-08, Vol.134, p.59-65

2019

Volltextzugriff (PDF)

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Journal of Nuclear Medicine, 2009-05, Vol.50 (Suppl_1), p.122S-150S

2009

Volltextzugriff (PDF)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper

Frontiers in oncology, 2022-01, Vol.11, p.800547-800547

2022

Volltextzugriff (PDF)

Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer

The oncologist (Dayton, Ohio), 2020-06, Vol.25 (6), p.515-522

2020

Volltextzugriff (PDF)

Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study

Neuroendocrinology, 2018, Vol.106 (Supplement: 1), p.171

2018

Volltextzugriff (PDF)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review

Oncotarget, 2016-05, Vol.7 (19), p.27848-27854

2016

Volltextzugriff (PDF)

Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives

World journal of gastroenterology : WJG, 2015-06, Vol.21 (21), p.6518-6525

2015

Volltextzugriff (PDF)

Predicting the radiotherapeutic treatment response of non-small cell lung cancer

Computer methods and programs in biomedicine update, 2022, Vol.2, p.100065, Article 100065

2022

Volltextzugriff (PDF)

CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden

Future oncology (London, England), 2022-04, Vol.18 (12), p.1449-1459

2022

Volltextzugriff (PDF)

Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer

The Journal of surgical research, 2022-10, Vol.278, p.223-232

2022

Volltextzugriff (PDF)

1 – 25 von 715

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(626)
Mit Volltextzugriff
(613)

Publikationsform

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(559)
Life Sciences & Biomedicine
(553)
Recist
(515)
Humans
(396)
Oncology
(333)
Female
(207)
Treatment Outcome
(202)
Male
(198)
Middle Aged
(187)
Aged
(179)
Radiology, Nuclear Medicine & Medical Imaging
(168)
Tumors
(163)
Adult
(139)
Response Evaluation Criteria In Solid Tumors
(137)
Medicine
(103)
Patients
(103)
Radiology
(102)
Retrospective Studies
(101)
Medicine & Public Health
(98)
Cancer
(86)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Response Evaluation Criteria in Cancer of the Liver (RECICL 2021 revised version)

P32 - AUTORECIST : utilisation de l'intelligence artificielle pour prédire la réponse RECIST

肝癌治療効果判定基準（第6版）（2021年改訂版）

Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know

mRECIST for HCC: Performance and novel refinements

RECIST 1.1—Update and clarification: From the RECIST committee

Dedicated software to harmonize the follow-up of oncological patients

Création d’un outil électronique d’évaluation de la réponse thérapeutique par l’imagerie en oncologie : le projet EVA

Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST

CO2.4 - Modèle multi-états pour l'estimation du meilleur timing de contrôle scannographique de progression du cancer du sein métastatique

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)

Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations

Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer

Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper

Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer

Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review

Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives

Predicting the radiotherapeutic treatment response of non-small cell lung cancer

CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden

Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer

Suchergebnisse filtern